🏢 官网IRWVECodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:30:00时区推断·⟳ 抓取 20:35:19·⚡ 决策 07-23 20:36:31 +1m12s·95.9 天前
Wave Life Sciences宣布将于2026年7月30日发布二季度财报并召开电话会
本次只是公司官方披露财报电话会排期，没有发布经营数据、临床进展、融资、合作或指引变化。
📄 原文WVE↗ 原文
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Analysts…
不做 Wave Life Sciences（WVE.US）
仅为二季度财报电话会排期公告，未披露业绩、管线、合作或指引增量，无法形成同向交易 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司官方披露财报电话会排期，没有发布经营数据、临床进展、融资、合作或指引变化。
主要风险
- 若7月30日正式财报或电话会披露超预期管线/现金流/指引信息，应由新信号重新研判。
原文全文
展开原文 · 1,944 字
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.
Following the live event, an archived version of the webcast will be available on the
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.
Following the live event, an archived version of the webcast will be available on the
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。